Showing 1141-1150 of 1539 results for "".
- Business News: Solta IPO Put on Icehttps://practicaldermatology.com/news/business-news-solta-ipo-put-on-ice/2461239/Bausch Health Companies Inc. is suspending its plans for the Solta IPO due to challenging market conditions and other factors. Bausch Health stated that the interests of the Company's stakeholders are best served in the near-term by focusing on driving Solta's revenue, profits a
- New Research Reveals Roughly 4 in 5 Acne Sufferers Have Missed Moments in Their Life Due to Acnehttps://practicaldermatology.com/news/new-research-reveals-roughly-4-in-5-acne-sufferers-have-missed-moments-in-their-life-due-to-acne/2461227/Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey released today. The survey was conducted on behalf of Cutera, Inc., which offers AviClear, the first
- Apyx Medical Corporation Receives FDA 510(k) Clearance for Renuvion Handpiecehttps://practicaldermatology.com/news/apyx-medical-corporation-receives-fda-510k-clearance-for-renuvion-handpiece/2461216/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to
- Verrica Receives Complete Response Letter from FDA for NDA for VP-102https://practicaldermatology.com/news/verrica-receives-complete-response-letter-from-fda-for-nda-for-vp-102/2461214/The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc.'s New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). According to the company, the only deficiency listed in the CRL was related to the deficiencies
- FDA Accepts Revance's BLA Resubmission for DaxibotulinumtoxinAhttps://practicaldermatology.com/news/fda-accepts-revances-bla-resubmission-for-daxibotulinumtoxina/2461167/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- FDA Cracks Down on OTC HQ Productshttps://practicaldermatology.com/news/fda-cracks-down-on-otc-hq-products/2461164/The US Food and Drug Administration is cracking down on over-the-counter (OTC) skin lightening products containing hydroquinone (HQ) that do not meet the requirements to be legally sold as OTC drugs. The group issued warning letters to 12 companies explaining that all OTC skin lightenin
- Botox Cosmetic Turns 20!https://practicaldermatology.com/news/botox-cosmetic-turns-20/2461158/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Bill Scott Named President of Endymed's US Subsidiaryhttps://practicaldermatology.com/news/bill-scott-named-president-of-endymeds-us-subsidiary/2461151/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- DERMWIRE Exclusive: FDA Clears Cutera’s AviClear Acne Devicehttps://practicaldermatology.com/news/dermwire-exclusive-fda-clears-cuteras-aviclear-acne-device/2461124/The U.S. Food and Drug Administration has cleared granted 510(k) clearance to Cutera’s AviClear acne device. This is the first energy device to receive a nod for the treatment of mild, moderate, and severe acne. AviClear targets acne at the source by selec